REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trials to treat mucopolysaccharidosis type II; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II disease; and RGX-501, which is in Phase I/II clinical trials to treat homozygous familial hypercholesterolemia. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. The company was formerly known as REGENX Biosciences, LLC and changed its name to REGENXBIO Inc. in September 2014. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone240-552-8181
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$218.51 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/14/2019 (Estimated)
OptionableOptionable
Regenxbio (NASDAQ:RGNX) Frequently Asked Questions
What is Regenxbio's stock symbol?
Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."
How were Regenxbio's earnings last quarter?
Regenxbio Inc (NASDAQ:RGNX) posted its earnings results on Wednesday, February, 27th. The biotechnology company reported $0.11 earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.43. Regenxbio had a return on equity of 22.33% and a net margin of 45.74%. View Regenxbio's Earnings History.
When is Regenxbio's next earnings date?
What price target have analysts set for RGNX?
7 equities research analysts have issued twelve-month price targets for Regenxbio's shares. Their forecasts range from $42.00 to $127.50. On average, they anticipate Regenxbio's share price to reach $81.6786 in the next twelve months. This suggests a possible upside of 39.4% from the stock's current price. View Analyst Price Targets for Regenxbio.
What is the consensus analysts' recommendation for Regenxbio?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 1 sell rating, 1 hold rating, 4 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.
Has Regenxbio been receiving favorable news coverage?
News coverage about RGNX stock has trended positive recently, InfoTrie reports. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Regenxbio earned a news impact score of 2.4 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 6.0 out of 10, meaning that recent news coverage is somewhat likely to have an impact on the stock's share price in the immediate future.
Who are some of Regenxbio's key competitors?
Some companies that are related to Regenxbio include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), argenx (ARGX), Ablynx (ABLYF), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Atara Biotherapeutics (ATRA) and Audentes Therapeutics (BOLD).
What other stocks do shareholders of Regenxbio own?
Who are Regenxbio's key executives?
Regenxbio's management team includes the folowing people:
- Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)
- Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)
- Dr. Olivier Danos, Chief Scientific Officer (Age 61)
- Mr. Curran M. Simpson, Sr. VP of Technical Operations (Age 57)
- Mr. Patrick J. Christmas II, Sr. VP & Gen. Counsel (Age 48)
Who are Regenxbio's major shareholders?
Regenxbio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include BlackRock Inc. (13.46%), RTW Investments LP (2.93%), FMR LLC (2.63%), Perceptive Advisors LLC (1.80%), Bank of New York Mellon Corp (1.48%) and Northern Trust Corp (1.15%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.
Which institutional investors are selling Regenxbio stock?
RGNX stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, FMR LLC, Voloridge Investment Management LLC, Gotham Asset Management LLC, Acadian Asset Management LLC, Chicago Equity Partners LLC, MetLife Investment Advisors LLC and GAM Holding AG. Company insiders that have sold Regenxbio company stock in the last year include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Insider Buying and Selling for Regenxbio.
Which institutional investors are buying Regenxbio stock?
RGNX stock was purchased by a variety of institutional investors in the last quarter, including Norges Bank, Dimensional Fund Advisors LP, Dimensional Fund Advisors LP, Perceptive Advisors LLC, Bank of New York Mellon Corp, BlackRock Inc., First Trust Advisors LP and Carmignac Gestion. View Insider Buying and Selling for Regenxbio.
How do I buy shares of Regenxbio?
Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Regenxbio's stock price today?
One share of RGNX stock can currently be purchased for approximately $58.58.
How big of a company is Regenxbio?
Regenxbio has a market capitalization of $2.13 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis.
What is Regenxbio's official website?
How can I contact Regenxbio?
Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]
MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
